<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23372725</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Study of the integrated immune response induced by an inactivated EV71 vaccine.</ArticleTitle><Pagination><StartPage>e54451</StartPage><MedlinePgn>e54451</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e54451</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0054451</ELocationID><Abstract><AbstractText Label="UNLABELLED">Enterovirus 71 (EV71), a major causative agent of hand-foot-and-mouth disease (HFMD), causes outbreaks among children in the Asia-Pacific region. A vaccine is urgently needed. Based on successful pre-clinical work, phase I and II clinical trials of an inactivated EV71 vaccine, which included the participants of 288 and 660 respectively, have been conducted. In the present study, the immune response and the correlated modulation of gene expression in the peripheral blood mononuclear cells (PBMCs) of 30 infants (6 to 11 months) immunized with this vaccine or placebo and consented to join this study in the phase II clinical trial were analyzed. The results showed significantly greater neutralizing antibody and specific T cell responses in vaccine group after two inoculations on days 0 and 28. Additionally, more than 600 functional genes that were up- or down-regulated in PBMCs were identified by the microarray assay, and these genes included 68 genes associated with the immune response in vaccine group. These results emphasize the gene expression profile of the immune system in response to an inactivated EV71 vaccine in humans and confirmed that such an immune response was generated as the result of the positive mobilization of the immune system. Furthermore, the immune response was not accompanied by the development of a remarkable inflammatory response.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT01391494 and NCT01512706.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Longding</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Science, Peking Union Medical College, Kunming, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hongling</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Haijin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rongcheng</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Zhaojun</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Teng</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lichun</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Chenghong</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Erxia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhenxin</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01391494</AccessionNumber><AccessionNumber>NCT01512706</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23372725</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pii">PONE-D-12-30148</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch M, Roos R (2006) Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology. D.M. Knipe and P.M. Howley, editors. Philadelphia, PA.: Lippincott Williams &amp; Wilkins 839&#x2013;893 pp.</Citation></Reference><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, et al. (2002) The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 34 Suppl 2S52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY (2007) Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics 120: e244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY (2003) Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9: 291&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, et al. (2010) EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 28: 3516&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, GPCDCP CAMS (2011) A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants [ClinicalTrials.gov study NCT01391494]. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/NCT01391494?term=ev71&amp;rank=5. Accessed 2012 April 26.</Citation></Reference><Reference><Citation>CAMS IMB (2012) A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants [ClinicalTrials.gov study NCT01512706]. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/NCT01512706?term=ev71&amp;rank=4. Accessed 2012 April 26.</Citation></Reference><Reference><Citation>JSPCDCP BVBC (2011) A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants [ClinicalTrials.gov study NCT01399853]. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/NCT01399853?term=ev71&amp;rank=1. Accessed 2012 May 29.</Citation></Reference><Reference><Citation>JSPCDCP BVBC (2010) A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children [ClinicalTrials.gov study NCT01267903]. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/NCT01267903?term=ev71&amp;rank=7. Accessed 2011 June 9.</Citation></Reference><Reference><Citation>SBC (2011) Guangxi Province Centers for Disease Control and Prevention [ClinicalTrials.gov study NCT01273246]. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/NCT01273246?term=ev71&amp;rank=15. Accessed 2011 July 21.</Citation></Reference><Reference><Citation>Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, et al. (1995) Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171 Suppl 1S44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876648</ArticleId></ArticleIdList></Reference><Reference><Citation>Faden H (1993) Poliovirus vaccination: a trilogy. J Infect Dis 168: 25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8515124</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">16571878</ArticleId></ArticleIdList></Reference><Reference><Citation>Beale AJ (1990) Polio vaccines: time for a change in immunisation policy? Lancet 335: 839&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">1969568</ArticleId></ArticleIdList></Reference><Reference><Citation>Flehmig B, Haage A, Pfisterer M (1987) Immunogenicity of a hepatitis A virus vaccine. J Med Virol 22: 7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">3035082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhiman N, Bonilla R, O&#x2019;Kane DJ, Poland GA (2001) Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20: 22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedognetti D, Wang E, Sertoli MR, Marincola FM (2010) Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 9: 555&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411321</ArticleId><ArticleId IdType="pubmed">20518712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya HI, Li S, Pulendran B (2011) Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 4: 193&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288517</ArticleId><ArticleId IdType="pubmed">22012654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Zhou X, Yang E, Pu J, Che Y, et al... (2012) Analysis of the Th1/Th2 Reaction in the Immune Response Induced by EV71 Inactivated Vaccine in Neonatal Rhesus Monkeys [published online ahead of print May 15, 2012]. J Clin Immunol doi:10.1007/s10875&#x2013;012&#x2013;9690&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875&#x2013;012&#x2013;9690&#x2013;3</ArticleId><ArticleId IdType="pubmed">22585051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, et al. (2003) Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188: 564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, et al. (2010) Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 6: 1028&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S-h, Liu J-s, Wang J-j, Shi H-j, Yang H-j, et al. (2009) Genetic Analysis of the VP1 Region of Human Enterovirus 71 Strains Isolated in Fuyang, China, During 2008. Virologica Sinica 24: 162&#x2013;170.</Citation></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269&#x2013;6275.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Long R, Li H, Chen H, Song X, et al. (2010) The Study of Detection Methods and Application of the Relative Potency in vitro of Inactivated Hepatitis A Vaccine (chinese). J Med Res 39: 50&#x2013;52.</Citation></Reference><Reference><Citation>Switula D (2000) Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics 6: 71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11273440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Lowe L, Wilson JD, Crowther E, Tzeggai K, et al. (1999) Simultaneous Quantification of Six Human Cytokines in a Single Sample Using Microparticle-based Flow Cytometric Technology. Clin Chem 45: 1693&#x2013;1694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cui W, Liu L, Wang J, Zhao H, et al. (2011) Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 91: 1337&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Zhang Y, Yang E, Liu L, Che Y, et al. (2012) The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates. Virology 432: 417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">22819834</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, et al. (2004) Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 78: 5820&#x2013;5834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC415835</ArticleId><ArticleId IdType="pubmed">15140980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones JO, Arvin AM (2003) Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol 77: 1268&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140848</ArticleId><ArticleId IdType="pubmed">12502844</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhao H, Zhang Y, Wang J, Che Y, et al. (2011) Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 412: 91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">21262515</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth R, Raymond FD, Makgoba MW (1991) Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 338: 83&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">1676471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, et al. (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177: 2051&#x2013;2055.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Su LY, Wu JM, Yu CK, et al. (2007) Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. Clin Microbiol Infect 13: 677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">17441979</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>